Charles River Labs Reports Q2 2026 Results and Raises Guidance

Details

reported second-quarter 2026 results with revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02. The company raised its 2026 revenue and non-GAAP earnings per share guidance, primarily driven by improving demand trends in the DSA segment and better-than-expected performance in the Manufacturing segment. Charles River also repurchased $100 million of common stock in the second quarter and completed divestitures of certain European Discovery Services sites, CDMO, and Cell Solutions businesses. The company further deepened its client relationships by joining Eli Lilly's TuneLab AI/ML platform and collaborating with Arovella Therapeutics.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.